List view / Grid view
13 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company will host a teleconference on Friday, October 31, 2014, at 2:30 p.m. EDT (1:30 p.m. CDT) to review data presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology (CMSTO) in Chicago...
13 October 2014 | By Probiodrug AG
Probiodrug AG announces the launch of its Initial Public Offering and listing on Euronext Amsterdam...
13 October 2014 | By Evotec
Evotec AG announced that its multi-target collaboration with Bayer HealthCare has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis...
13 October 2014 | By ABPI and OBN
The ABPI, which represents large, medium and small innovative research-based biopharmaceutical companies in the UK and OBN, the membership organisation that brings together the UK’s emerging life sciences companies, corporate partners and investors are delighted to announce their commitment to working together under a Memorandum of Understanding...
13 October 2014 | By MSD
NICE draft guidance says no to biologic treatments for patients with moderate-to-severe ulcerative colitis – potentially missing the opportunity to provide an alternative...
10 October 2014 | By B&W Tek
B&W Tek, Inc. is pleased to announce that our newest handheld Raman system, the TacticID-N, has recently received some exceptional praise from a United States federal law enforcement agency...
10 October 2014 | By Janssen
New data demonstrates efficacy and safety of OLYSIO® (simeprevir) in broader patient populations...
10 October 2014 | By Janssen
Persistence of STELARA® (ustekinumab) significantly better than Anti-TNFs in treatment of Psoriasis according to observational study analysis...
10 October 2014 | By Advanced Cell Diagnostics, Inc
Advanced Cell Diagnostics, Inc. has been awarded a two-year, $1.4 million grant from National Cancer Institute...
10 October 2014 | By The Harvard Stem Cell Institute
Giant step toward new diabetes treatment...
10 October 2014 | By AstraZeneca
AstraZeneca announced that The Lancet Respiratory Medicine has published positive safety and efficacy data from a Phase IIb study evaluating benralizumab, a novel investigational monoclonal antibody, in patients with severe, uncontrolled asthma and elevated levels of eosinophils, a type of inflammatory white blood cell...
9 October 2014 | By Embo Medical
Early-stage medical device company is developing minimally invasive embolization technology for the treatment of wide variety of diseases...
9 October 2014 | By Bone Therapeutics
Four German centres now approved to assess novel allogeneic regenerative therapy for the treatment of delayed union fractures...
9 October 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces the signing of a preferred access agreement with Mayo Clinic...
9 October 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has accepted to file the company's supplemental Biologics License Application and granted Priority Review of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans...
